THRB and metabolic syndrome: In conclusion, last decade has seen a reawakening of interest in developing TRβ selective TH analogs, and at the present there is renewed hope for novel tissue- and/or isoform-selective thyromimetics to find application in therapy for the treatment of dyslipidemia and liver-related life threatening conditions, as well as for disabling diseases of the CNS, such as MS.